Torrent Pharmaceuticals earnings calls.

Torrent Pharma delivered a robust Q3 FY26 with consolidated revenues of INR 3,303 croreCurrent reported value: INR 3,303 crore. No comparable prior figure is available in the source record., up 18Current 18 crore vs previous available quarter 10 crore.% YoY, driven by strong branded market performance (75% of revenue). India grew 14% with 5.5% volume outperformance versus IPM's 1.2%, while Brazil delivered 27% growth (13% secondary sales). EBITDA margin expanded to 32.9Current 32.9 crore vs previous available quarter 32.3 crore.%. The JB Pharma acquisition closed with 48.8% stake on January 21, with line-by-line consolidation from Q4. Management guided JB margin improvement to 32-33% (from JB's current ~28-29%) and cost synergies of INR 400-450 croreCurrent INR 400-450 crore. Reported change: Over 2-3 years. over 2-3 years (20% in year one). Germany remains impacted by third-party supplier disruption (down 6% CC), with resolution unlikely for 3-4 quarters. US sales of $36M up 12% with 5-7 annual launches targeted, aiming to cross $200M annually by FY27. Brazil GLP-1 (Semaglutide) filing awaiting ANVISA approval with priority review status. Key risk: integration execution at JB amid CEO/CFO resignations and Q4 business practice adjustments.